XML 20 R6.htm IDEA: XBRL DOCUMENT v3.23.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 3 Months Ended
Jul. 01, 2023
Jul. 02, 2022
Cash Flows from Operating Activities:    
Net income $ 41,042 $ 19,877
Non-cash items:    
Depreciation and amortization 23,032 22,447
Share-based compensation expense 6,989 5,299
Amortization of deferred financing costs 830 797
Inventory reserve adjustment (1,785) (2,075)
Other non-cash operating activities 682 1,192
Change in operating assets and liabilities:    
Change in accounts receivable 1,010 10,358
Change in inventories (29,396) 15,240
Change in prepaid income taxes 1,595 2,118
Change in other assets and other liabilities (9,986) (6,079)
Change in accounts payable and accrued expenses (14,927) (27,181)
Net cash provided by operating activities 19,086 41,993
Cash Flows from Investing Activities:    
Capital expenditures (9,663) (45,467)
Acquisition 0 (2,850)
Proceeds from sale of property, plant and equipment 402 498
Other investments (6,000) (10,395)
Net cash used in investing activities (15,261) (58,214)
Cash Flows from Financing Activities:    
Repayment of term loan borrowings (1,750) (4,375)
Contingent consideration payments (849) (21,593)
Proceeds from employee stock purchase plan 2,871 2,459
Proceeds from exercise of stock options 627 127
Cash used to net share settle employee equity awards (1,483) 0
Other financing activities (14) (13)
Net cash used in financing activities (598) (23,395)
Effect of exchange rates on cash and cash equivalents (1,974) (4,932)
Net Change in Cash and Cash Equivalents 1,253 (44,548)
Cash and Cash Equivalents at Beginning of Period 284,466 259,496
Cash and Cash Equivalents at End of Period 285,719 214,948
Supplemental Disclosures of Cash Flow Information:    
Transfers from inventory to fixed assets for placement of Haemonetics equipment $ 1,982 $ 38,022